Simris Alg AB (publ) (SIMRIS-B.ST)
SEK 0.07
(-1.75%)
SEK 0.07
(-1.75%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2 Million SEK | -4944.88% |
| 2022 | -742 Thousand SEK | 64.1% |
| 2021 | -2.06 Million SEK | 24.81% |
| 2020 | -2.74 Million SEK | -97.91% |
| 2019 | -1.38 Million SEK | -368.15% |
| 2018 | -296.69 Thousand SEK | -112.01% |
| 2017 | 2.47 Million SEK | 433.03% |
| 2016 | -741.75 Thousand SEK | -220.03% |
| 2015 | 618 Thousand SEK | -42.72% |
| 2014 | 1.07 Million SEK | -45.89% |
| 2013 | 1.99 Million SEK | 229.87% |
| 2012 | 604.5 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -9.03 Million SEK | -2.54% |
| 2024 Q2 | -9.94 Million SEK | 97.45% |
| 2023 Q1 | 141 Thousand SEK | 114.2% |
| 2023 Q3 | 1.27 Million SEK | 2663.04% |
| 2023 Q2 | 46 Thousand SEK | -67.38% |
| 2023 FY | -37.43 Million SEK | -4944.88% |
| 2023 Q4 | -8.81 Million SEK | -793.39% |
| 2022 FY | -742 Thousand SEK | 64.1% |
| 2022 Q2 | 81 Thousand SEK | -10.99% |
| 2022 Q3 | 79 Thousand SEK | -2.47% |
| 2022 Q4 | -993 Thousand SEK | -1356.96% |
| 2022 Q1 | 91 Thousand SEK | 134.21% |
| 2021 Q3 | -1.55 Million SEK | -578.7% |
| 2021 Q1 | -574 Thousand SEK | 26.5% |
| 2021 Q2 | 324 Thousand SEK | 156.45% |
| 2021 FY | -2.06 Million SEK | 24.81% |
| 2021 Q4 | -266 Thousand SEK | 82.85% |
| 2020 Q1 | -678 Thousand SEK | -479.49% |
| 2020 FY | -2.74 Million SEK | -97.91% |
| 2020 Q3 | 120 Thousand SEK | 108.51% |
| 2020 Q2 | -1.41 Million SEK | -107.96% |
| 2020 Q4 | -781 Thousand SEK | -750.83% |
| 2019 Q4 | -117 Thousand SEK | 71.67% |
| 2019 Q3 | -413 Thousand SEK | 75.75% |
| 2019 Q2 | -1.7 Million SEK | -301.78% |
| 2019 Q1 | 844 Thousand SEK | 385.43% |
| 2019 FY | -1.38 Million SEK | -368.15% |
| 2018 Q1 | -237 Thousand SEK | -130.26% |
| 2018 Q3 | -176 Thousand SEK | -142.72% |
| 2018 Q4 | -295.69 Thousand SEK | -68.01% |
| 2018 FY | -296.69 Thousand SEK | -112.01% |
| 2018 Q2 | 412 Thousand SEK | 273.84% |
| 2017 FY | 2.47 Million SEK | 433.03% |
| 2017 Q4 | 783.25 Thousand SEK | 66.3% |
| 2017 Q3 | 471 Thousand SEK | -14.52% |
| 2017 Q2 | 551 Thousand SEK | -16.89% |
| 2017 Q1 | 663 Thousand SEK | 182.69% |
| 2016 Q1 | -546 Thousand SEK | -215.19% |
| 2016 Q2 | -295 Thousand SEK | 45.97% |
| 2016 Q3 | 901 Thousand SEK | 405.42% |
| 2016 FY | -741.75 Thousand SEK | -220.03% |
| 2016 Q4 | -801.75 Thousand SEK | -188.99% |
| 2015 Q2 | -523 Thousand SEK | -150.24% |
| 2015 Q3 | 876 Thousand SEK | 267.5% |
| 2015 Q4 | 474 Thousand SEK | -45.89% |
| 2015 Q1 | -209 Thousand SEK | 0.0% |
| 2015 FY | 618 Thousand SEK | -42.72% |
| 2014 FY | 1.07 Million SEK | -45.89% |
| 2013 FY | 1.99 Million SEK | 229.87% |
| 2012 FY | 604.5 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 101.249% |
| Ziccum AB (publ) | -23.28 Million SEK | 108.619% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 99.42% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 95.197% |
| Mendus AB (publ) | 28.48 Million SEK | 92.955% |
| Genovis AB (publ.) | 54 Million SEK | 96.283% |
| Intervacc AB (publ) | -13.79 Million SEK | 114.55% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 7.554% |
| Active Biotech AB (publ) | -1.67 Million SEK | 219.821% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 79.855% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 92.517% |
| Aptahem AB (publ) | 2.63 Million SEK | 23.707% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 158.667% |
| Kancera AB (publ) | -1.96 Million SEK | 202.137% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -2506.494% |
| Fluicell AB (publ) | 1.73 Million SEK | -15.478% |
| Saniona AB (publ) | 11.78 Million SEK | 82.964% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 139.222% |
| Biovica International AB (publ) | 6.87 Million SEK | 70.816% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 108.62% |
| AcouSort AB (publ) | 8.38 Million SEK | 76.076% |
| Xintela AB (publ) | 78 Thousand SEK | -2473.077% |
| Abliva AB (publ) | -35.66 Million SEK | 105.628% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 101.366% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 28.5% |
| OncoZenge AB (publ) | 3000.00 SEK | -66800.0% |
| Amniotics AB (publ) | -1.93 Million SEK | 203.99% |
| 2cureX AB (publ) | -37.48 Million SEK | 105.354% |
| CombiGene AB (publ) | -21.29 Million SEK | 109.427% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 574.468% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 99.822% |
| Camurus AB (publ) | 1.58 Billion SEK | 99.873% |
| Corline Biomedical AB | 28.38 Million SEK | 92.928% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 101.635% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 105.832% |
| I-Tech AB | 27.56 Million SEK | 92.719% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 97.171% |
| Cyxone AB (publ) | 2.61 Million SEK | 23.133% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 41.023% |
| Biosergen AB | -456 Thousand SEK | 540.132% |
| Cantargia AB (publ) | -3.45 Million SEK | 158.157% |
| NextCell Pharma AB | -43.74 Million SEK | 104.588% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 121.829% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 82.11% |
| Nanologica AB (publ) | -76 Thousand SEK | 2740.789% |
| SynAct Pharma AB | -778 Thousand SEK | 357.969% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 1139.896% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 115.532% |
| Lipum AB (publ) | 53 Thousand SEK | -3686.792% |
| BioInvent International AB (publ) | 71.46 Million SEK | 97.191% |
| Alzinova AB (publ) | 19.87 Million SEK | 89.901% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 94.471% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -37.182% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 13480.0% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -21.049% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 156.061% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 94.329% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 291.325% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 35.94% |